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INTRODUCTION
Severe thrombocytopenia is the inevitable consequence
of myeloablative conditioning regimens used for hemato-
poietic stem cell transplantation (HSCT). Severe thrombocy-
topenia necessitates platelet transfusion for the management
and prevention of bleeding. The speed of recovery of platelet
counts after both autologous and allogeneic HSCT is depen-
dent on several factors, including source of stem cells, cell
doses infused, types and phases of disease, graft-versus-host
disease (GVHD), infections, and cytomegalovirus (CMV)
serology at transplantation [1-8].
After primary recovery of peripheral blood counts after
transplantation, there can be a late decline of platelet
counts, although the counts of other cell lineages may
remain near or in normal ranges. This secondary failure of
platelet recovery (SFPR) can result in prolonged severe
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ABSTRACT
After primary recovery of platelet counts after transplantation, there can be a late persistent decline called secondary
failure of platelet recovery (SFPR), which may occur although the counts of other cell lineages remain within the
normal range. SFPR was defined as a decline of platelet counts below 20,000/µL for 7 consecutive days or requiring
transfusion support after achieving sustained platelet counts ≥50,000/µL without transfusions for 7 consecutive days
after hematopoietic stem cell transplantation (HSCT). The study population consisted of 2871 consecutive patients
receiving transplants from January 1990 to March 1997. After primary recovery of platelet counts, SFPR not due to
relapse of the underlying disease was observed in 285 of 1401 (20%) patients undergoing allogeneic transplantation
and 36 (8%) of 444 patients undergoing autologous transplantation, with a median time of onset after transplantation
at day 63 (range, day 21-156) and day 44 (range, day 24-89), respectively. Concomitant neutropenia was seen in 57
(20%) of 285 patients undergoing allogeneic HSCT and 7 (19%) of 36 patients undergoing autologous HSCT with
SFPR. By multivariable analysis, the following were factors significantly associated with SFPR after allogeneic HSCT:
a transplant from an unrelated donor; a graft-versus-host disease (GVHD) prophylaxis other than methotrexate and
cyclosporine; development of grade 2 through 4 acute GVHD; impaired renal or liver function; conditioning with the
combination of busulfan, cyclophosphamide, and total body irradiation; stem cell dose; and infections.
Cytomegalovirus infection after engraftment and source of stem cells were the only significant risk factors after
autologous HSCT. The hazard rate of death was significantly higher in patients who experienced SFPR (hazard
ratio = 2.6 for allogeneic HSCT; hazard ratio = 2.2 for autologous HSCT). SFPR was associated with serious compli-
cations and poor outcome after transplantation. The identification of the characteristics and risk factors for SFPR
could improve patient counseling and management and lead to the design of effective treatment strategies.
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thrombocytopenia in which patients again require platelet
support. Thrombocytopenia can result from different fac-
tors that either affect the production of platelets in the mar-
row or cause decreased platelet survival in the peripheral
circulation. Disease recurrence and allograft rejection are
important causes of thrombocytopenia. Nonetheless, trans-
plant patients can develop isolated thrombocytopenia in the
absence of disease relapse or graft rejection, indicating the
existence of other pathophysiological mechanisms that are
currently poorly deﬁned. This study describes the incidence,
clinical features, risk factors, and outcome of SFPR due to
causes not related to disease recurrence in a large series of
patients undergoing HSCT.
MATERIALS AND METHODS
Study Population
The study population consisted of 2871 consecutive
patients undergoing HSCT at the Fred Hutchinson Cancer
Research Center (FHCRC) between January 1, 1990, and
March 31, 1997. All patients were treated after obtaining
informed consent. Data for long-term follow-up was col-
lected on FHCRC Protocol 999. Clinical and laboratory
data were extracted from the computerized database and
from the research charts. Patients were categorized accord-
ing to type of transplant (allogeneic versus autologous). All
patients were evaluated from the day of transplantation,
deﬁned as day 0, until the ﬁrst occurrence of one of the fol-
lowing events: relapse, second transplantation, last routine
follow-up before discharge to home, or death.
Definitions
Primary platelet recovery after myeloablative condition-
ing regimens was deﬁned as an increase in platelet counts to
≥50,000/µL for 7 consecutive days without transfusion sup-
port. SFPR was deﬁned as a decline of platelet counts below
20,000/µL, lasting at least 7 consecutive days or requiring
platelet transfusions within 7 days, after achieving primary
platelet recovery. The first of the 7 consecutive days of
thrombocytopenia with platelet counts below 20,000/µL
was considered the day of onset of SFPR.
Risk Factor Analysis
To identify risk factors associated with the hazard rate of
development of SFPR, the following variables were evalu-
ated: age at transplantation, patient sex, type of donor,
source of stem cells (bone marrow versus peripheral blood),
cell dose infused (either CD34+ cell or total nucleated cell
counts), conditioning regimens, CMV serology at transplan-
tation, pretransplantation platelet count, and presence of
underlying disease. These underlying diseases were further
categorized as low risk, intermediate risk, and high risk. The
low-risk group was composed of patients with chronic
myelogenous leukemia (CML) in the chronic phase. The
high-risk group was composed of patients in relapse under-
going transplantation and CML patients in blast crisis. All
other patients were categorized into the intermediate-risk
group. For patients undergoing allogeneic HSCT, other
variables included in the analysis were patient/donor sex,
patient/donor CMV status at transplantation, development
of acute GVHD, and GVHD prophylaxis other than
methotrexate (MTX) plus cyclosporine (CSP)—the current
standard regimen at our institution [9].
Renal and liver functions were evaluated based on serum
creatinine and bilirubin levels, respectively, and were con-
sidered continuous variables throughout the study period.
Infections were evaluated from the time of primary platelet
recovery in all patients. Systemic bacterial and fungal infec-
tions were documented by positive blood cultures. Viral
infections were documented by the onset of viremia or by
positive centrifugation cultures (shell vial) from blood sam-
ples and/or detection of positive antigenemia for CMV.
In patients who developed SFPR, the incidence of con-
comitant neutropenia was assessed, deﬁned as at least 2 con-
secutive absolute neutrophil counts (ANC) of <1000/µL on
2 different days during the week before or after the day of
onset of SFPR. Presence of the thrombotic thrombocy-
topenic purpura/hemolytic uremic syndrome (TTP/HUS)
was based on chart review of haptoglobin, lactate dehydro-
genase (LDH), and serum creatinine values; Coombs test;
the presence of schistocytes on the peripheral blood smear;
and the documented evaluations of primary care providers
and attending physicians. LDH was considered abnormally
high if it was >250 U/dL, whereas haptoglobin was consid-
ered abnormally low if it was <26 mg/dL. The criteria for
the diagnosis of TTP/HUS were the presence of Coombs-
negative hemolytic anemia with schistocytes and thrombo-
cytopenia with or without renal abnormalities.
Marrow Assessment
Pathology reports of bone marrow aspirates, obtained
from the posterior iliac crest of thrombocytopenic patients
after the onset of SFPR and adjusted for age categories [10],
were reviewed to correlate marrow cellularity and presence
of megakaryocytes with SFPR. Data on cellularity were
divided into 3 groups: marrow cellularity with and without
the presence of megakaryocytes <35% of normal, ≥35% but
<50% of normal, and ≥50% of normal.
Transfusion Requirements
The platelet transfusion guidelines at our center before
1993 were to maintain platelet counts above 20,000/µL.
After 1993, stable patients followed as outpatients received
transfusions at platelet counts <10,000/µL, whereas inpa-
tients, if less stable or early after HSCT, routinely received
transfusions at platelet counts <20,000/µL. For invasive
diagnostic procedures required after HSCT, it was standard
practice to maintain platelet counts of >20,000/µL for 1 day
for bronchoscopy, ≥50,000/µL for 1 day for central line
placement or lumbar punctures, ≥50,000/µL for 3 days for
endoscopy of the gastrointestinal tract with biopsy, and
>50,000 to 70,000/µL for 5 days for major surgery.
In the present article, platelet transfusion requirements
were determined for all patients from transplantation to the
day of second transplantation, discharge home, relapse, or
death. Total transfusion events, in addition to total transfu-
sion events divided by the number of days of observation,
were assessed. A single transfusion event was considered
equivalent to a pool of 6 units of random-donor platelets
obtained from whole-blood units or single-donor platelets
collected by platelet pheresis. A more formal comparison of
transfusion requirements among the groups listed was not
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done because the transfusion requirements contributed to
the deﬁnition of each group.
Long-Term Follow-Up
Data on 1-year mortality, causes of death, and late com-
plications were obtained from research charts, hometown
physician notes, and autopsy reports. Platelet recovery from
SFPR was assessed in patients alive at 1 year and deﬁned as
recovery of self-sustained platelet counts of >50,000/µL, as
described above, that occurred within 1 year ± 3 months
from transplantation. This time frame was chosen to evalu-
ate all data collected from primary physicians or obtained
from the work-up performed for the 1-year follow-up evalu-
ation at the FHCRC.
Statistical Methods
Proportional hazard rate regression models were ﬁt to
examine the association of the factors previously listed with
the of SFPR among patients who achieved primary platelet
recovery. The data were left truncated so that a patient did
not enter the risk set for SFPR until primary platelet recov-
ery was achieved. Patients who were classiﬁed as not having
failed were censored in regression models at the minimum of
time of death, second transplantation, discharge home, or
relapse. Patients who relapsed within 30 days from the onset
of SFPR were reclassiﬁed as not having failed. Interactions
between selected variables were examined as needed in
regression models, and the assumption of proportional haz-
ard rates was tested by including a term representing the log-
arithm of time (where time represents time to SFPR). The
effect of SFPR on mortality was examined among patients
who achieved primary platelet recovery using proportional
hazard rates regression models. SFPR was regarded as a
time-dependent covariate for these purposes, and the data
were left truncated as before. Patients, therefore, were not
regarded as failures until the time of SFPR, and patients did
not enter the risk set until primary recovery was achieved.
Treating SFPR as a time-dependent covariate dealt with the
lead-time bias that was incurred by categorizing patients as
failures posttransplantation. Explanatory variables that were
correlated were examined by comparing regression models
with both sets of variables to models containing only 1 set of
the correlated variables using the likelihood ratio test. All
analyses were conducted separately for the data from autolo-
gous and allogeneic transplants. All P values associated with
regression models were derived from the Wald test, and no
adjustments were made for multiple comparisons.
RESULTS
Secondary Failure of Platelet Recovery After
Allogeneic Stem Cell Transplantation
A total of 2153 patients received an allogeneic trans-
plant during the study period, and 1401 (65%) achieved pri-
mary platelet recovery. After primary platelet recovery, 821
of 1401 (59%) maintained platelet counts of ≥50,000/µL for
the entire observation period. Of the 1401 patients, 250
(18%) had a decline to <50,000/µL but not <20,000/µL after
primary recovery, and the remaining 330 (24%) had a
decline to <20,000/µL after primary recovery. Of the
330 patients, 45 relapsed within 1 month of SFPR and were
regarded as nonfailures for the purposes of the analysis.
Characteristics of patients who achieved primary recovery
are reported in Table 1.
The adjusted incidence of SFPR not due to disease recur-
rence was 20% (285/1401). Median day of onset was day 63
(range, day 21-156) posttransplantation. Of the 70%
(199/285) of patients who were discharged home at a median
of day 103 (range, day 61-305), only 28% (56/199) had recov-
ered to sustained platelet counts >50,000/µL by the time of
discharge, with a median duration of SFPR of 25.5 days
(range, day 3-89). The overwhelming majority (96.2%) of
patients who did not develop SFPR had follow-up discontin-
ued because they were discharged home. The median dura-
tion of the observation period of these patients was 94 days.
Overall, 141 patients who developed SFPR were alive at
1 year. At this time, 86% (121/141) had platelet counts
>50,000/µL (64% [77/121] had platelet counts >150,000/µL),
and 6% (8/141) had platelet counts <50,000/µL. Data on
platelet counts were available on the other 11 patients
Table 1. Patient Characteristics*
Allogeneic Autologous
Patients Patients
n 1401 444
Age at transplantation, y 34.8 (0.3-67.0) 43.6 (0.4-68.3)
Cell dose, TNCs  106 per kg 2.6 (0.05-36.3) 6.2 (0.1-80.0)
Patient/donor sex
M/M 449 (32) 168 M (38)
M/F 317 (23) —
F/M 364 (26) 276 F (62)
F/F 271 (19) —
Median baseline platelet count 76,000 112,000
Acute GVHD
Grades 0-1 393 (28) —
Grades 2-4 967 (69) —
Unknown 41 (3) —
Type of donor
Matched sibling 758 (54) —
Mismatched related 190 (14) —
Unrelated 450 (32) —
Source of stem cells
Bone marrow 1296 (93) 137 (31)
Peripheral blood 101 (7) 286 (64)
Bone marrow and peripheral 4 (<1) 21 (5) 
blood
Diagnosis
Low-risk 423 (30) 7 (2)
Intermediate-risk 561 (40) 172 (23)
High-risk 417 (30) 265 (39)
Conditioning regimen
TBI >12 cGy 581 (41) 4 (1)
TBI ≤12 cGy 304 (22) 104 (23)
BuCy 326 (23) 61 (14)
BuCy TBI 80 (6) 39 (9)
Other 110 (8) 236 (53)
GVHD prophylaxis
MTX + CSP 1267 (90) —
Other 134 (10) —
*Data are median (range) or n (%). TNC indicates total nucleated
cell; GVHD, graft-versus-host disease; TBI, total body irradiation;
Bu, busulfan; Cy, cyclophosphamide; MTX, methotrexate; CSP,
cyclosporine.
Platelet Recovery After Stem Cell Transplantation
157B B & M T
between 4 and 9 months (n = 2) or after 15 months (n = 9),
all of whom had platelet counts >50,000/µL. There was
1 patient for whom there was no long-term data on platelet
counts. Clinical extensive chronic GVHD occurred in 71%
(101/141) of these patients, and 2.5% (5/141) of patients had
limited chronic GVHD.
Concomitant neutropenia was seen in 20% (57/285) of
patients, and of these, 56% (32/57) were on ganciclovir.
Thrombocytopenia was ascribed to TTP/HUS in 5% (15
of 285) of patients. Bacterial and fungal infections were
documented in 24.5% (70 of 285) of patients after primary
platelet engraftment. CMV infection was documented in
27% (79 of 285) of patients by CMV antigenemia (24% [69
of 285]) or by blood culture (11.5% [33 of 285]). No cases
of graft rejection were identified in this group of patients
with SFPR.
Bone marrow aspirates were performed in 64% (183 of
285) of thrombocytopenic patients at a median of 11 days
(range, 0-72 days) after the onset of SFPR. Overall cellular-
ity was read as <35% of normal in 35% (64 of 183) of
patients, with 61 of the 64 (95%) showing trilineage
engraftment and 3 (5%) showing amegakaryocytosis. Cellu-
larity was ≥35% but <50% of normal in 14% (25 of 183) of
patients, with 1 of the 25 (4%) showing relative reduction of
megakaryocytes. Cellularity with trilineage engraftment was
read as ≥50% of normal in 51% (94 of 183) of patients, with
relative reduction of megakaryocytes in 6% (6 of 94).
Risk Factor Analysis.Univariate models for SFPR are
illustrated in Table 2. By multivariable analysis, transplants
from unrelated donors, GVHD prophylaxis other than
Table 2. Univariate Models for Secondary Failure of Platelet Recovery
Among Allogeneic and Autologous Patients*
Hazard Ratio 95% CI P
Allogeneic patients
Age at transplantation† 1.1 1.0-1.2 .007
Disease risk
Low 1 — —
Intermediate 1.2 0.9-1.6 .25
High 1.4 1.1-1.9 .02
Preparative regimen
TBI ≤12 cGy 1 — —
TBI >12 cGy 1.2 0.9-1.6 .21
BuCy 0.6 0.4-0.9 .009
BuCy TBI 1.7 1.1-2.7 .02
Other 1.0 0.6-1.6 .89
Patient/donor CMV serology
–/– 1 — —
–/+ 0.8 0.5-1.2 .30
+/– 0.8 0.6-1.2 .27
+/+ 1.1 0.8-1.5 .46
Patient sex
M 1 — —
F 1.0 0.8-1.3 .78
Patient/donor sex
M/M 1 — —
M/F 1.0 0.7-1.4 .96
F/M 1.1 0.8-1.5 .38
F/F 0.9 0.6-1.3 .51
Type of donor
Matched sibling 1 — —
Related HLA-mismatched 1.2 0.9-1.8 .22
Unrelated 1.5 1.1-1.9 .003
GVHD prophylaxis
Other regimen 1 — —
CSP + MTX 0.5 0.4-0.8 .0007
Acute GVHD‡
Grades 0-1 1 — —
Grades 2-4 4.7 3.2-7.1 <.0001
Cell dose§ 0.98 0.94-1.02 .31
Baseline platelet count 0.94 0.89-0.99 .02
Bilirubin level¶ 1.2 1.1-1.2 <.0001
Creatinine level¶ 1.6 1.2-2.1 .0004
Infections‡
Bacterial 2.3 1.8-2.9 <.0001
Fungal 6.2 3.8-10.0 <.0001
CMV 1.6 1.2-2.1 .0004
Autologous patients
Age at transplantation† 1.3 1.0-1.7 .08
Disease risk
Intermediate 1 — —
Low 0.4 0.1-1.2 .09
High 0.7 0.3-1.6 .38
Preparative regimen
TBI ≤12 cGy 1 — —
TBI >12 cGy — — —
BuCy 0.4 0.1-1.9 .24
BuCy TBI 2.1 0.8-5.9 .14
Other 1.1 0.5-2.5 .83
Patient CMV serology
Negative 1 — —
Positive 1.7 0.8-3.6 .17
Patient sex
M 1 — —
F 1.1 0.6-2.2 .80
Continued
Table 2. Continued
Hazard Ratio 95% CI P
Source of stem cells
BM 1 — —
PBSCs 2.4 1.0-5.7 .05
BM + PBSCs 4.8 1.5-15.1 .008
Cell dose§ 1.02 1.0-1.04 .07
Baseline platelet count 0.90 0.70-1.15 .39
Bilirubin level¶ 1.1 0.9-1.3 .34
Creatinine level¶ 1.3 0.4-4.5 .71
Infections‡
Bacterial 1.3 0.5-3.3 .62
Fungal 2.8 0.7-11.5 .16
CMV 4.4 1.9-10.1 .0004
*TBI indicates total body irradiation; Bu, busulfan; Cy, cyclophos-
phamide; CMV, cytomegalovirus; GVHD, graft-versus-host disease;
CSP, cyclosporine; MTX, methotrexate; BM, bone marrow; PBSC,
peripheral blood stem cell.
†Modeled as a continuous variable; hazard ratio is presented per
decade.
‡Treated as a time-dependent covariate.
§Modeled as a continuous variable; hazard ratio presented per 1 
106 cells/kg.
 Modeled as a continuous variable; hazard ratio presented per
50,000 platelets/µL.
¶Treated as a time-dependent covariate, where the covariate is the
average value of the appropriate parameter in a 15-day interval.
Treated as a continuous variable; 1 U = 1 mg/dL.
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MTX plus CSP, stem cell dose per kilogram, and prepara-
tive regimen were variables signiﬁcantly associated with the
hazard rate of SFPR among patients achieving primary
recovery (Table 3). Development of acute GVHD, impaired
renal and liver functions, and infections after primary
platelet recovery were time-dependent variables signifi-
cantly associated with the hazard rate of SFPR. After con-
sideration of each of these variables, none of the other
factors examined signiﬁcantly improved the model (as deter-
mined by the likelihood ratio test). Prophylaxis for GVHD
and preparative regimen were each associated with the risk
of the underlying disease. A higher proportion of high-risk
patients for the underlying disease received prophylaxis
other than MTX and CSP, and patients who received >12 cGy
total body irradiation (TBI) or the combination of busulfan,
cyclophosphamide, and TBI were more likely to be high- or
intermediate-risk patients. Type of donor and GVHD pro-
phylaxis were also correlated with the development of acute
GVHD. If underlying disease risk was added to the model
summarized in Table 3, the resulting model was not signiﬁ-
cantly improved (P = .85). If, on the other hand, underlying
disease risk was substituted for GVHD prophylaxis in the
model shown in Table 3, addition of prophylaxis to such a
model provides a significant improvement (P = .004). If
preparative regimen is deleted from the model shown in
Table 3, adding this variable suggestively improves the
model (P = .02). If underlying disease risk replaces prepar-
ative regimen in Table 3, addition of preparative regimen
to the resulting model yields a suggestive improvement
(P = .07). If GVHD prophylaxis, occurrence of GVHD
grades 2 through 4, or donor type is deleted from the
model in Table 3, addition of each of these variables signifi-
cantly or suggestively improves the model resulting from
the deletion of each variable (P = .003, P < .0001, P = .10,
respectively).
Platelet Transfusion Requirements.Transfusion require-
ments for patients who received allogeneic transplants are
reported in Table 4. The patients with SFPR required more
transfusion support.
Survival.The 1-year mortality of the patients develop-
ing SFPR was 51% (144/285). Of the patients, 30%
(86/285) died before leaving FHCRC, and 21% (58/285)
died after being discharged home. Causes of death are
reported in Table 5. No graft rejection events occurred as a
cause of death. When treated as a time-dependent covariate,
development of SFPR was significantly associated with an
increased hazard rate of mortality (hazard ratio = 2.6; 95%
CI, 2.1-3.1, P < .0001) among patients who achieved pri-
mary recovery after adjusting for patient age at transplanta-
tion, risk of disease, GVHD prophylaxis, patient/donor
CMV serostatus, type of donor, and preparative regimen. A
total of 86% (48/56) of patients who had platelet recovery
Table 3. Risk Factors Associated With the Development of Secondary Fail-
ure of Platelet Recovery by Multivariable Regression*
Hazard Ratio 95% CI P
Allogeneic patients
Type of donor
Matched sibling 1.0 — —
Related HLA-mismatched 1.2 0.8-1.8 .41
Unrelated 1.4 1.0-2.0 .03
GVHD prophylaxis
Other regimen 1.0 — —
CSP + MTX 0.5 0.3-0.7 .0006
Acute GVHD
Grade 0-1 1.0 — —
Grade 2-4 3.5 2.2-5.5 <.0001
Preparative regimen
TBI ≤12 cGy 1 — —
TBI >12 cGy 1.3 0.9-1.8 .14
BuCy 0.9 0.6-1.4 .59
BuCy TBI 2.0 1.1-3.4 .02
Other 1.8 1.0-3.2 .05
Average bilirubin level†‡ 1.13 1.09-1.17 <.0001
(as continuous variable)
Average creatinine level†‡ 1.9 1.4-2.5 <.0001
(as continuous variable)
Infections†
Bacterial 1.8 1.3-2.3 <.0001
Fungal 4.1 2.4-7.1 <.0001
CMV 1.4 1.1-1.9 .01
Autologous patients
Infections†
CMV 4.0 1.7-9.1 .001
Source of stem cells
BM 1 — —
PBSCs 2.1 0.9-5.0 .10
BM + PBSCs 4.5 1.4-14.5 .01
*GVHD indicates graft-versus-host disease; CSP, cyclosporine;
MTX, methotrexate; TBI, total body irradiation; Bu, busulfan; Cy,
cyclophosphamide; CMV, cytomegalovirus; BM, bone marrow; PBSC,
peripheral blood stem cell.
†Modeled as a time-dependent covariate (for bilirubin and creati-
nine levels, 1 U = 1 mg/dL).
‡Value taken as average level in 15-day windows.
Table 4. Platelet Transfusion Requirement*
Transfusion Events/
Transfusion Events Days at Risk
Allogeneic patients
>50,000/µL 8 (0-78) 0.08 (0-1.4)
20,000-50,000/µL 11.5 (2-95) 0.11 (0.02-1.22)
SFPR (<20,000 µL) 22 (4-167) 0.23 (0.03-1.37)
Autologous patients
>50,000/µL 5 (0-85) 0.09 (0-0.89)
20,000-50,000/µL 6 (0-85) 0.1 (0-0.9)
SFPR (<20,000/µL) 13 (1-133) 0.15 (0.01-0.15)
*Data are median (range). SFPR indicates secondary failure of
platelet recovery. All patients achieved primary platelet recovery and
maintained platelet counts >50,000/µL, decreased to 20,000 to
50,000/µL, or had SFPR (<20,000/µL). Transfusion Events refers to
the median total number of transfusion events (a single transfusion
event was considered the equivalent to a pool of 6 U of random-donor
platelets obtained from whole-blood units or single-donor platelets col-
lected by platelet pheresis) administered per patient throughout the
study period. Transfusion Events/Days at Risk refers to the median
number of transfusion events administered per patient per day during
the observation period.
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by the time of discharge home and 65% (93/143) who were
still thrombocytopenic upon discharge were alive at 1 year.
Secondary Failure of Platelet Recovery After
Autologous Stem Cell Transplantation
A total of 718 patients received an autologous trans-
plant during the study period, and 444 (62%) achieved pri-
mary platelet recovery. After primary platelet recovery,
353 (80%) of 444 patients maintained platelet counts
≥50,000/µL for the entire observation period. Of the 444
(11%) patients, 51 had a decline in platelet count to
<50,000/µL but not <20,000/µL after primary recovery, and
the remaining 40 (9%) had a decline in platelet count to
<20,000/µL after primary recovery. Of the 40 patients, 4
relapsed within 1 month of SFPR and were therefore
regarded as nonfailures for purposes of analysis. Character-
istics of patients who achieved primary recovery are
reported in Table 1.
Median day of onset of SFPR was day 44 (range, day
24-89) posttransplantation. Of 36 patients, 23 were dis-
charged to home at a median of day 89 (range, day 40-169),
and 48% (11 of 23) had recovered to sustained platelet
counts with a median duration of SFPR of 10 days (range,
1-92 days). As part of a tandem transplantation protocol, 3
additional patients underwent a second transplantation
before leaving FHCRC. The overwhelming majority
(95.9%) of patients who did not develop SFPR had follow-
up discontinued because they were discharged home. The
median duration of the observation period of these patients
was 54 days.
Among the 20 patients who developed SFPR and were
alive at 1 year, 11 (55%) had platelet counts >50,000/µL, and
5 of 11 were within normal ranges (ie, with platelet counts
>150,000/µL). One patient had a platelet count <50,000/µL
at 1 year. Data were only available on 6 of these 20 patients,
all of whom had platelet counts >50,000/µL, between 4 and
9 months (n = 2) or after 15 months (n = 4). There were 2 patients
for whom there were no long-term data on platelet counts.
Concomitant neutropenia was seen in 7 (19%) of 36
patients with SFPR, and 4 of the 7 were on ganciclovir.
Bone marrow aspirates were performed in 13 (36%)  of
36 thrombocytopenic patients at a median of 15 days (range,
0-44 days) after the onset of SFPR. Cellularity was read as
<35% of normal with no megakaryocytes in 1 of 13 patients
as ≥35% of <50% and as ≥50%, with trilineage engraftment
in 3 of 13, and 9 of 13 patients, respectively.
Risk Factor Analysis.Univariate models are reported in
Table 2. Only CMV infection after primary platelet recov-
ery and source of stem cells were significantly associated
with the hazard rate of SFPR. The multivariable regression
model containing each of these variables is summarized in
Table 3. Addition of age failed to provide a significant
improvement in this model (P = .33). Cell dose is highly
correlated with source of stem cells, but the addition of cell
dose to a model already containing a source of stem cells
adds little (P = .60). If one considered the total of primary
and secondary failure of platelet recovery combined, there
was a 40% and 19% incidence after marrow or peripheral
blood stem cell (PBSC) infusion, respectively. Therefore,
although there was an increase in the hazard rate of SFPR
among those who achieved primary recovery after PBSC
infusion, there was a reduction in the overall incidence of
failure of platelet recovery.
Platelet Transfusion Requirements.Transfusion require-
ments for patients undergoing autologous transplantation
are reported in Table 4.
Survival.The 1-year mortality of the patients develop-
ing SFPR was 44% (16 of 36), and 27% (10 of 36) died
before leaving the center. When treated as a time-depen-
dent covariate, SFPR was associated with an increased haz-
ard rate of death (hazard ratio = 2.2; 95% CI, 1.4-3.3; P =
.0005) among patients who achieved primary recovery after
adjusting for age at transplantation, risk of underlying dis-
ease, and preparative regimen. Causes of death are reported
in Table 5.
DISCUSSION
SFPR is a signiﬁcant complication after HSCT that is
associated with a poor prognosis. We noted incidences of
20% in allogeneic HSCT recipients and 5% in autologous
HSCT recipients. This study likely underestimates the true
incidence because patients may develop SFPR after being
discharged home, and we were unable to detect such fail-
ures. The problems of thrombocytopenia and delayed pri-
mary recovery of platelet counts after HSCT have been
addressed in several reports [1-5]. However, no previous
large study has speciﬁcally addressed the issue of thrombo-
cytopenia developing after primary platelet recovery. The
analysis of characteristics and risk factors for SFPR are help-
ful in possibly identifying underlying causes, which are not
otherwise clinically evident.
In a recent multicenter study, Bernstein et al. [2] showed
that time to primary platelet recovery after allogeneic and
autologous HSCT was influenced by baseline clinical and
time-dependent variables. These clinical variables were: the
number of CD34+ cells infused, pretransplantation platelet
count, prior radiation therapy, disease type, type of allogeneic
donor, fever, and veno-occlusive disease of the liver. Other
Table 5. Causes of Death at the 1-Year Follow-Up of Patients Developing
Secondary Failure of Platelet Recovery*
Allogeneic Autologous
Patients Patients
Total number 144 16
Other infections/sepsis 46 (31) 2 (12.5)
Graft-versus-host disease 27 (18) —
Noninfectious pulmonary complications 26 (18) 3 (19)
Aspergillus pneumonia 25 (17) —
Cytomegalovirus pneumonia 15 (10) —
Venous occlusive disease 11 (8) 5 (31)
Hemorrhage 11 (8) 1 (6)
Relapse† 10 (7) 2 (12.5)
TTP/HUS 2 (1.5) 1 (6)
Other — 4 (25)
*Data are n or n (%). TTP/HUS indicates thrombotic thrombocy-
topenic purpura/hemolytic uremic syndrome.
†Relapse occurred >1 month after the onset of secondary failure of
platelet recovery.
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studies have reported enhanced platelet recovery with the use
of PBSCs and with greater numbers of CD34+ cells infused
[6-8]. Our analysis did not associate source of stem cells
among allogeneic recipients or disease type and disease status
with a higher risk of development of SFPR, suggesting that
SFPR was not inﬂuenced by some of the pretransplantation
factors that signiﬁcantly correlate with primary platelet recov-
ery. Source of stem cells was suggestively associated with
SFPR among the patients undergoing autologous transplan-
tation, but this was likely related to the fact that more patients
were at risk for SFPR after the use of PBSCs. The association
of growth factors with SFPR was not included in the analysis
because the observed association could have been related to
the clinical reasons that growth factors were started.
The only baseline clinical variables signiﬁcantly associ-
ated with SFPR among allogeneic transplantations were
transplants from an alternative donor, regimens for GVHD
prophylaxis different from the standard combination with
CSP and MTX, cell dose infused, and preparative regimen
[9]. The effect of CSP and MTX did not appear to be com-
pletely explained by the correlation of nonstandard GVHD
prophylaxis with risk of underlying disease or by the reduc-
tion of the rate of GVHD among patients who received
CSP and MTX. Adding GVHD prophylaxis to a regression
model that already contained risk of disease and presence of
GVHD led to a signiﬁcant improvement in the model. The
majority of patients undergoing allogeneic transplantation
received CSP and MTX, and if the analysis was restricted to
this group, the overall conclusions were not qualitatively
changed (data not shown). The development of acute
GVHD (grade 2 to 4) showed a signiﬁcant association with
the hazard rate of SFPR, even after adjusting for other pre-
transplantation and posttransplantation variables, in particu-
lar, variables associated with development of GVHD. Simi-
larly, both the type of GVHD prophylaxis and type of
allogeneic donor showed a significant association with the
hazard rate of SFPR, even after considering the contribu-
tion of GVHD. This result suggested that each of these
parameters contributed to the hazard rate of SFPR above
and beyond the effect due to GVHD. The development of
GVHD had previously been associated with thrombocy-
topenia [11,12].
In the present report, elevated serum bilirubin levels
were used as a surrogate marker for liver dysfunction.
Hepatic veno-occlusive disease (VOD) has been associated
with persistent thrombocytopenia and refractoriness to
platelet transfusions [13,14]. However, the liver dysfunction
associated with SFPR was characterized by a median time of
onset at day 63, and therefore, many cases were likely
related to GVHD or infections rather than VOD [15].
TTP/HUS has been associated with CSP and FK506
toxicities, GVHD, and radiotherapy [16,17]. The incidence,
time of onset, and outcome of TTP/HUS vary greatly in
HSCT [18-21], and the clinical diagnosis may be difficult
[22]. Thrombocytopenia, Coombs-negative hemolytic ane-
mia, renal abnormalities, fever, and altered sensorium
[23,24] represent a constellation of features of TTP/HUS
that, either isolated or in combination, can be caused by a
variety of factors. Red blood cell fragmentation is not spe-
ciﬁc for TTP/HUS after transplantation because it is also
reported in patients without TTP/HUS [16,25,26]. Our
study reports clinical evidence of TTP/HUS in only 5% of
patients developing SFPR. However, this retrospective
analysis may underestimate the true incidence of this prob-
lem, and TTP/HUS should always be considered in the
differential diagnosis of SFPR.
Systemic fungal and bacterial infections were factors asso-
ciated with SFPR. Severe thrombocytopenia also occurs in
patients with sepsis in the nontransplant setting [27]. It is pos-
sible that a common mechanism(s) contributes to the throm-
bocytopenic states associated with infections or inﬂammatory
diseases [27,28]. One proposed mechanism is a cytokine
storm effect, with increased levels of granulocyte colony-
stimulating factor, macrophage colony-stimulating factor, and
other cytokines, that may activate the monocyte/macrophage
system, causing a premature removal of platelets from the cir-
culation (R.A.N., unpublished observations) [29-34].
CMV infections have been shown to be associated with
secondary marrow graft failure after allogeneic bone mar-
row transplantation [35]. In addition, isolated thrombocy-
topenia has also been observed during CMV infection [36].
Various mechanisms of marrow suppression have been pro-
posed, including direct infection of hematopoietic pro-
genitors, stromal cells or accessory cells leading to cell
death, abnormal gene expression, or immune reaction
against the infected cells [37-40]. In vitro studies have
shown that latent CMV infections can become reactivated
during megakaryocytic maturation leading to thrombocy-
topenia through direct infection [41].
After autologous HSCT, the incidence of SFPR was
lower than that after allogeneic HSCT. This is likely related
to an increased risk of GVHD and infections after allo-
geneic HSCT but could also be related to the relative
shorter length of follow-up among patients who underwent
autologous transplanatation. The relatively low incidence of
SFPR after autologous HSCT decreased the statistical
power to detect signiﬁcant predisposing factors among the
variables analyzed. There was an apparent increase in the
risk of SFPR after autologous HSCT with PBSCs, but a
signiﬁcantly higher proportion of autologous bone marrow
recipients had either primary or secondary failure when
compared with PBSC recipients. The apparent increased
risk of SFPR among those who achieved primary recovery
was likely related to the rapid primary recovery of platelet
counts after autologous PBSC transplantation and the very
low incidence of primary failure of platelet recovery; there-
fore, factors (ie, CMV) that may have contributed to delayed
or failed primary platelet recovery after autologous marrow
transplantation caused SFPR instead [1,4].
In summary, SFPR is a significant complication after
HSCT. The etiology of SFPR in many cases is likely multi-
factorial. No events of graft rejection were identified in
patients with SFPR. Relapse should always be considered
because 13% of patients with SFPR had relapsed within
30 days of onset. The identification of this complication
with a description of characteristics and risk factors should
improve patient counseling and management. Improved
supportive care and prevention of GVHD may reduce the
incidence of SFPR. Clinical trials of agents to shorten the
duration of thrombocytopenia after transplantation must
also consider the incidence, clinical characteristics, and risk
factors associated with SFPR in their study design.
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